Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2022 - 2025)

Tarsus Pharmaceuticals (TARS) has 4 years of Amortization of Deferred Charges data on record, last reported at $156000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 168.97% year-over-year to $156000.0; the TTM value through Dec 2025 reached $593000.0, up 84.16%, while the annual FY2025 figure was $593000.0, 47.51% up from the prior year.
  • Amortization of Deferred Charges reached $156000.0 in Q4 2025 per TARS's latest filing, up from $152000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $217000.0 in Q3 2023 and bottomed at $21000.0 in Q2 2024.
  • Average Amortization of Deferred Charges over 4 years is $100562.5, with a median of $112500.0 recorded in 2023.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 65.85% in 2023, then surged 595.24% in 2025.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $126000.0 in 2022, then dropped by 11.9% to $111000.0 in 2023, then plummeted by 47.75% to $58000.0 in 2024, then skyrocketed by 168.97% to $156000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $156000.0 in Q4 2025, $152000.0 in Q3 2025, and $146000.0 in Q2 2025.